tirzepatide surpass-4 The SURPASS 1-5 study as an evaluation of in monotherapy or Tirzepatide: A Systematic Update

GLP-1 agonists overall were associated with a 3.67 times higher risk of developing gastroparesis compared to non-users, but within that elevated risk category, tirzepatide appears significantly safer than semaglutide

Measuring inconsistency in meta-analyses

Blood sugar-related side effects Blood sugar-related side effects with Mounjaro are uncommon but can occur, particularly in people with diabetes who take other glucose-lowering medicines

While Tirzepatide is generally well tolerated, it may cause side effects such as nausea, diarrhea, and decreased appetite, which are typically mild to moderate

This option may be particularly helpful for people who struggle with food cravings or emotional eating

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial